Last $147.33 USD
Change Today +0.39 / 0.27%
Volume 49.8K
BAYRY On Other Exchanges
Symbol
Exchange
BrsaItaliana
Xetra
Mexico
Continuous
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-sponsored adr (BAYRY) Snapshot

Open
$146.32
Previous Close
$146.94
Day High
$147.50
Day Low
$146.32
52 Week High
11/24/14 - $147.72
52 Week Low
04/15/14 - $124.36
Market Cap
121.8B
Average Volume 10 Days
43.0K
EPS TTM
--
Shares Outstanding
826.9M
EX-Date
04/25/14
P/E TM
--
Dividend
$2.90
Dividend Yield
1.97%
Current Stock Chart for BAYER AG-SPONSORED ADR (BAYRY)

bayer ag-sponsored adr (BAYRY) Related Bloomberg News

View More Bloomberg News

bayer ag-sponsored adr (BAYRY) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as contraceptives, hemophilia treatments, anticoagulants, and medicines to treat multiple sclerosis, cancer, hypertension, and infectious diseases; and consumer health products comprising over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; contrast agent injection systems for diagnostic and therapeutic medical procedures in computed tomography, magnetic resonance imaging, and molecular imaging; and mechanical systems for removing thrombi from blood vessels, as well as service products for its systems. The CropScience segment offers products for use in agriculture as insecticides, fungicides, and herbicides or seed treatments; seeds and plant traits; and various products for gardens, green industry, and nonagricultural pest control. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and functional films; and produces and markets inorganic basic chemicals. The company has a strategic alliance with OncoMed Pharmaceuticals, Inc. to develop drugs to target cancer stem cell therapeutics. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

107,700 Employees
Last Reported Date: 02/28/14
Founded in 1863

bayer ag-sponsored adr (BAYRY) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €2.9M
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €1.8M
Labor Director and Member of Management Board
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

bayer ag-sponsored adr (BAYRY) Key Developments

Cinven, EQT, KKR Reportedly Plans To Bid For Bayer's Diabetes Unit

Bayer AG (DB:BAYN) is exploring the sale of its diabetes device business, reported Bloomberg citing people with knowledge of the matter. Bayer is working with Credit Suisse Group AG on the potential sale, three of the people said, asking not to be identified because the process is private. The people said that Cinven Limited, EQT Partners AB, KKR & Co. L.P. (NYSE:KKR) and Triton may consider bidding for the unit, which could fetch between €1 billion and €2 billion. Representatives for Bayer, Credit Suisse, Zoetis, KKR, Cinven, EQT and Triton declined to comment to Bloomberg.

Bayer Said To Explore Sale of Diabetes Unit

Bayer AG (DB:BAYN) is exploring the sale of its diabetes device business as the German company focuses on faster-growing medicines, according to people with knowledge of the matter. Bayer is working with Credit Suisse Group AG on the potential sale, three of the people said, asking not to be identified because the process is private. Cinven Limited, EQT Partners AB and Triton Advisers Ltd. may consider bidding for the unit, which could fetch between €1 billion and € 2 billion, the people said.

William Ackman May Sell Its Stake In Zoetis

William Ackman may sell stake in Zoetis Inc. (NYSE:ZTS) to Valeant Pharmaceuticals International, Inc. (TSX:VRX), according to people familiar with the matter. A spokesman for Zoetis said that the company got a call from William Ackman regarding the investment, but declined to comment on it. Valeant isn’t alone among potential suitors for Zoetis. Novartis AG (SWX:NOVN) and Bayer AG (BUSE:BAYER) also expressed interest in the company, people familiar with the matter have said.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYRY:US $147.33 USD +0.39

BAYRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,479 GBp +14.00
Merck & Co Inc $59.75 USD +0.41
Pfizer Inc $31.10 USD +0.63
Sanofi €77.23 EUR +0.80
Dow Chemical Co/The $51.76 USD +0.37
View Industry Companies
 

Industry Analysis

BAYRY

Industry Average

Valuation BAYRY Industry Range
Price/Earnings 26.4x
Price/Sales 2.3x
Price/Book 4.8x
Price/Cash Flow 26.3x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-SPONSORED ADR, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.